- Date: December 12, 2016
A new diagnostic tool for endometrial cancer, an innovative therapy to treat leukaemia, and a device for rehabilitation after knee surgery are three outstanding examples of the 20 projects chosen for this year’s CaixaImpulse programme.
Jordi Portabella, Director of Research and Knowledge at the ”la Caixa” Banking Foundation, and Carlos Trenchs, Managing Director at Caixa Capital Risc, presented the innovative proposals today, 3 of which belong to the field of life sciences, while 17 belong to the medical sciences and healthcare sectors.
In the 2016 edition, research centres, hospitals, and universities from autonomous communities such as Andalusia (1), Catalonia (16), Galicia (1), Navarre (1), and Valencia (1) have taken part.
Of the 73 projects that were initially submitted, a committee of experts have chosen the 20 finalists, which will receive financial support of up to 70,000 euros as well as a comprehensive programme of training and expert advice.
Valuation and commercialisation, pending challenges
According to the Innovation Union Scoreboard 2016 (IUS) report, Spain has cutting-edge infrastructure, first-rate research centres, and professionals. Nevertheless, it is ranked 21st in the European Union (EU) for innovation.
In order to help change this reality, Obra Social ”la Caixa” and Caixa Capital Risc launched CaixaImpulse, the first comprehensive programme in Spain for the creation of biotechnology companies.
Both institutions use their expertise in the fields of research, the creation, development and investment in early-stage companies for a common aim: the transfer of research results to society.
April 17, 2020
EIT Health, which supports CaixaImpulse, offers a number of online tools to bring its network together to respond to the pandemic.
December 17, 2019
More than 1000 health innovation delegates from across the globe gathered in Paris earlier this month for the EIT Health Summit 2019.
November 26, 2019
The EntrepreneurXXI Awards is an annual competition for Spanish and Portuguese startups with high impact potential.